Company* (Symbol)

Product

Description

Indication

Status (Date)

CANCER

AEterna Laboratories (Canada; AELA)

Neovastat/AE-941

Orally bioavailable

Renal cell carcinoma naturally occurring antiangiogenic product that blocks VEGF and MMPs

Phase III results presented at the 25th European Society for Medical Oncology showing Neovastat blocks two angiogenesis regulators (10/16)

Allos Therapeutics Inc. (ALTH)

RSR13

Synthetic small molecule that increases the release of oxygen from hemoglobin

Glioblastoma multiforme and brain metastases

Company announced positive extended-survival data of two Phase II trials presented at the 42nd Annual Meeting of the American Society of Therapeutic Radiation and Oncology (10/25)

AltaRex Corp. (Canada; TSE:AXO; OTC BB:ALRXF)

OvaRex

Modified murine monoclonal antibody that binds to CA125 cancer antigen

Ovarian cancer

Company reported clinical data from its double-blind, placebo-controlled lead OvaRex trial; data demonstrated a positive association between specific immune responses from OvaRex and clinical benefit (10/24)

AltaRex Corp. (Canada; TSE:AXO; OTC BB:ALRXF)

BrevaRex-MAb

Modified murine monoclonal antibody against the MUC1 cancer antigen

Multiple myeloma and breast, lung and ovarian cancers

Company announced preliminary Phase I data demonstrating activation of cellular immune responses (10/24)

Antigenics Inc. (AGEN)

Oncophage

Cancer vaccine consisting of purified, patient-specific, heat shock protein-peptide complexes

Soft tissue cancer (sarcoma)

Company initiated a Phase II trial (10/17)

AVI BioPharma Inc. (AVII)

Avicine

Therapeutic vaccine that elicits an immune response to human chorionic gonadotropin hormone

Cancer

Company presented an update on the development of Avicine and its NeuGene gene-targeted drugs at the Biotechnology and Converging Information Technology Companies of the 21st Century conference; AVI plans to initiate Phase III trials for Avicine later this year and clinical trials for NeuGene in cancer and polycystic kidney disease (10/19)

Calydon Inc.*

CN706

Oncolytic virus designed to kill only tumor cells

Prostate cancer

Phase I/II study results showed that PSA levels decreased from baseline in nine of the 11 patients treated at the two highest dose levels; adenoviral replication was demonstrated and the drug was well tolerated; results were presented at the American Society for Therapeutic Radiology and Oncology conference (10/24)

Cell Pathways Inc. (CLPA)

Aptosyn and CP461

Exisulind; two selective antineoplastic agents combined with gemcitabine, vinorelbine or irinotecan

Non-small-cell lung cancer

Research showed that Aptosyn and CP461 enhance the anti-proliferative effects of chemotherapeutic drugs on non-small-cell lung cancer cell lines; data were presented at the European Society for Medical Oncology (10/16)

Corixa Corp. (CRXA)

Melacine

Vaccine consisting of lysed (broken) cells from two human melanoma cell lines combined with Corixa's Detox adjuvant, which includes monophosphoryl lipid A and mycobacterial cell wall skeleton

Stage II melanoma

Phase III data presented at the Society of Biological Therapy meeting showed Melacine vaccination was found to provide a statistically significant benefit in terms of prolongation of disease-free survival (10/30)

Direct Therapeutics Inc.*

DTI-015

Contains carmustine dissolved in absolute

Glioblastoma multiforme ethanol

Enrollment began for two Phase I/II trials (10/3)

Galenica Pharmaceuticals Inc.*

GPI-0100

Semi-synthetic saponin derivative

Prostate cancer

Company announced the publication of data in the July 15 issue of Vaccine that suggest that GPI-0100 adjuvants may retain production of both humoral and cell-mediated immunity and may be useful in the development of vaccines against tumors and infectious agents; product is in a Phase I trial for prostate cancer (10/24)

Genzyme Molecular Oncology (GZMO)

Dendritic/cancer cell fusion

Technology combining a patient's dendritic cells with his inactivated tumor cells in a chemical fusion procedure; the fused cells are injected back into the patient

Melanoma and kidney cancer

Company initiated two Phase I/II trials enrolling 20 patients each (10/3)

Isis Pharmaceuticals Inc. (ISIP)

ISIS 3521

Antisense protein kinase C-alpha inhibitor that binds to an mRNA sequence specific to PKC-alpha

Non-small-cell lung cancer

Company said the first patient has been dosed in a Phase III trial to evaluate the ability of the drug to safely prolong patients' lives when given in combination with carboplatin and paclitaxel (10/18)

Lorus Therapeutics Inc. (Canada; LORFF; TSE:LOR)

GTI-2040

Antisense anticancer therapeutic

Cancer

Company has decided to move the drug into Phase II clinical trials (10/17)

MediGene AG* (Germany) and Schering AG (Germany)

HPV16L1E7CVLP

Fusion protein, which self-assembles to form chimeric virus-like particles that cause a pseudo-infection; comprised of an L1 structural protein and part of the E7 early viral protein

Precancerous lesions of the cervix

Companies began Phase I/II trials to treat lesions caused by the human papilloma virus (11/1**)

Maxim Pharmaceuticals (MAXM)

Maxamine

Histamine dihydrochloride

Advanced metastatic melanoma

Phase III trial results were presented at the European Society of Medical Oncology conference showing Maxamine used with interleukin-2 significantly improved survival for patients with liver metastases compared with those treated with IL-2 alone (10/16)

Matrix Pharmaceuticals Inc. (MATX)

Intradose injectable gel

Cisplatin/epinephrine

Unresectable liver metastases from colorectal cancer

Company said Phase II results showed 6 of 9 patients experienced a complete response or total reduction of viable tumor volume; results were presented at the 25th annual meeting of the European Society for Medical Oncology (10/12)

MedImmune Inc. (MEDI) and Alza Corp. (NYSE:AZA)

Ethyol (FDA-approved)

Amifostine

Head and neck cancer

American Society of Clinical Oncology published pivotal Phase III results of cancer patients receiving radiation therapy (10/4)

MGI Pharma Inc. (MOGN)

MGI 114

Irofulven; hydroxymethyl-acylfulvene

Cancer

Company announced interim results from a Phase II dose-escalation trial; irofulven demonstrated anticancer activity, including an objective response and stable disease (10/16); company selected pancreatic cancer as the first tumor target; pivotal Phase III will begin enrolling patients near the end of the year (10/23)

NeoRx Corp. (NERX)

Skeletal Targeted Radiotherapy

Small-molecule carrier of the radionucleotide holmium-166

Multiple myeloma

Company initiated Phase III trials at 20 major cancer centers in the U.S. and Canada (10/2)

Oxigene Inc. (OXGN)

Declopramide

Apoptosis-inducing drug that increases the vulnerability of cancer cells to conventional forms of chemotherapy and radiation

Cancer

Researchers reported Phase I results at the 25th European Society for Medical Oncology Congress; the company now intends to initiate Phase II trials (10/16)

Pharmacia Corp. (NYSE:PHA)

Aromasin

Exemestane tablets

Breast cancer

Presented early results from a Phase II study at the European Society for Medical Oncology; study compared Aromasin with tamoxifen (10/13)

Pharmacia Corp. (NYSE:PHA)

SU5416

A synthetic small-molecule inhibitor that blocks the vascular endothelial growth

Colorectal cancer

Presented Phase I/II study results of SU5416 in combination with 5-FU/leucovorin; tumors were reduced by greater than 50% in 37% of patients (10/13)

Pharmacyclics Inc. (PCYC)

Xcytrin

Motexafin gadolinium injection

Metastasized brain cancer and glioblastoma

Reported results from the leadin phase of the ongoing, randomized Phase III trial and of a Phase I safety trial at the 42nd Annual Meeting of the American Society for Therapeutic Radiology and Oncology; Xcytrin appeared to improve local control in the brain (10/25)

QLT Inc. (Canada; QLTI)

Verteporfin

Using photodynamic therapy

Melanoma

Company announced positive Phase II results of 54 patients with 98% of assessed tumors showing a complete clinical response 6 months after initial treatment (10/31)

Seattle Genetics Inc.*

SGN-15

Monoclonal antibody; single-chain immunotoxin

Advanced breast carcinoma

Company initiated a Phase II trial that will test SGN-15 in combination with Taxotere (10/31)

Techniclone Corp. (TCLN)

Cotara

Tumor necrosis therapy; chimeric monoclonal anti-body that targets DNA-associated histone antigens, labeled with I-131

Colorectal cancer

Company announced that patient enrollment for a Phase I study has started at the Stanford University Medical School (10/18)

Valentis Inc. (VLTS)

Combination gene medicine

Interleukin-2 plus Super-antigen-B

Melanoma

Company announced positive interim results from a Phase I/IIa trial showing the combination gene medicine appears safe (10/3)

Zeltia-PharmaMar (Spain)

ET-743

Ecteinascidin; compound obtained from the tunicate Ecteinascidia turbinata

Sarcoma

Company said clinical results support future development; ET-743 exhibited lasting benefits in a variety of sarcomas, as well as breast, womb and ovarian cancers (10/18)

CARDIOVASCULAR

Amylin Pharmaceuticals Inc. (AMLN)

AC3056

Antioxidant that inhibits vascular cell adhesion molecule expression in human vascular cells

Atherosclerosis

Company completed its first Phase I study of AC3056 to prevent restenosis following angioplasty and other procedures to open clogged arteries and in the treatment of artherosclerosis (10/2)

AVI BioPharma Inc. (AVII)

Resten-NG

Compound from AVI's third-generation Neugene antisense technology that targets the genetic sequence c-myc

Cardiovascular restenosis

AVI selected Texas Cardiac Center as the second research site to participate in its Phase II study to evaluate the effectiveness of Resten-NG (10/26)

Genzyme Surgical Products (GZSP)

Gene therapy product

Based on an engineered form of HIF-1a, hypoxia inducible factor, which triggers the body's protective response to oxygen starvation

Coronary artery disease

Company initiated a Phase I trial in patients with coronary artery disease undergoing bypass surgery who have an area of the heart that is not suitable for surgical revascularization (10/2)

InterMune Pharmaceuticals Inc. (ITMN)

Actimmune

Interferon gamma-1b

Idiopathic pulmonary fibrosis

Company started a Phase III trial (10/3)

CENTRAL NERVOUS SYSTEM

Biogen Inc. (BGEN)

Avonex (FDA-approved)

Interferon beta-1a

Multiple sclerosis

Company began a new clinical trial to assess the long-term effect of treatment with Avonex (10/17); company also announced at the 125th Annual Meeting of the American Neurological Association that an in vitro study showed that Avonex is the most potent on a mass basis of the three commercially available beta interferon drugs used to treat MS (10/17)

Medeva Pharmaceuticals Inc. (unit of Celltech Group; UK; NYSE:CLL; LSE:CCH)

Methylphenidate

Methylphenidate hydrochloride

Attention deficit hyperactivity disorder

Company reported Phase III data at the 47th annual American Academy of Child and Adolescent Psychiatry that showed the drug controlled symptoms of ADHD throughout the school day without the need for a second midday dose (10/27)

Nastech Pharmaceutical Co. Inc. (UK; NSTK)

Intranasal morphine

>

Formulation of dosages up to 20 mg

Pain

Company reported Phase II data at the International Conference on New Approaches to Pain Management, showing the product was safe and efficacious in the treatment of breakthrough pain (10/12)

NeoTherapeutics Inc. (NEOT)

Neotrofin

Leteprinim potassium

Alzheimer's disease

Company announced that patients who received Neotrofin once daily, orally, in a Phase II study showed a statistically significant improvement in the Neuropsychiatric Inventory rating scale over the course of 90 days (10/26)

Pain Therapeutics Inc. (PTIE)

PTI-701

Painkiller

Pain

Company announced positive safety and efficacy results of a Phase II dose-ranging study conducted in 300 patients following oral surgery (10/3)

DIABETES

Galileo Laboratories Inc.*

NIS215

Nutrition therapy

Type II diabetes

Company initiated clinical studies of NIS215 that will evaluate improvements of end-organ function; primary study end-points include improvements in glucose control and renal function (10/23)

Ista Pharmaceuticals Inc. (ISTA)

Vitrase

Injectable enzyme; hyaluronidase

Diabetic retinopathy

Company announced interim< results of a pilot Phase IIa study showing that Vitrase can safely induce a posterior vitreous detachment in patients with diabetic retinopathy (10/18)/P>

Questcor Pharmaceuticals Inc. (AMEX:QSC)

Emitasol

Metoclopramide; nasal spray

Diabetic gastroparesis

Company announced Phase II results that showed both Emitasol and oral metoclopramide were bioavailable and that Emitasol may enhance the clinical response versus oral metoclopramide (10/19)

INFECTION

Aquila

Quilimmune Biopharmaceuticals Inc. (AQLA)

Vaccine; based on carbohydrate antigens from S. pneumoniae and its family

Pneumococcal infections

Company initiated a third clinical study to evaluate the safety and immunogenicity of Quilimmune formulations (10/19)

Avant Immunotherapeutics Inc. (AVAN)

Peru-15

Cholera vaccine

Cholera

Company started a placebo-controlled, double-blind Phase IIb study of Peru-15 at the Children's Hospital in Cincinnati (10/16)

Axcan Pharma Inc. (AXCA)

Helicide

Bismuth-based single triple capsule containing colloidal bismuth subcitrate (40 mg), metronidazole (125 mg) and tetracycline (125 mg)

Helicobacter pylori

Company announced final results of the Phase III North American pivotal clinical trial, which confirm that Helicide has the potential to be used as a first-line therapy (10/16)

Centaur Pharmaceutical Inc.

CPI-1189

Small-molecule agent that modifies cellular response to stress

AIDS dementia complex (ADC)

Interim results of a Phase IIa trial show CPI-1189 was well tolerated with more than 90% of treated patients completing the initial 10-week dosing period (10/19)

Enzo Biochem Inc. (NYSE:ENZ)

HGTV-43

Gene medicine incorporating two technologies, genetic antisense and a vector to deliver the anti-sense molecule to the cell

HIV

Company reported Phase I data showing Enzo-engineered cells successfully engrafted in a patient's bone marrow and were spawning new differentiated CD4+ cells (10/2)

Enzo Biochem Inc. (NYSE:ENZ)

EHT899

Orally available viral protein

Hepatitis B virus

Company reported that 80% of the patients in a Phase I trial responded favorably as measured by a decrease in viral load, a decrease in liver inflammation or reduction of elevated levels of liver enzymes (10/31)

Enzon Inc. (ENZN) and Schering-Plough Corp. (NYSE:SGP)

PEG-Intron injection

Peginterferon-alfa-2b

Chronic hepatitis C

Schering-Plough reported Phase III results at the 51st Annual Meeting of the American Association for the Study of Liver Diseases that showed combination therapy with PEG-Intron and Rebetol (ribavirin, USP) capsules achieved a 54% rate of sustained virologic response overall (10/30)

Gilead Sciences Inc. (GILD)

Adefovir dipivoxil

Reverse transcriptase inhibitor

Hepatitis B virus

Company announced data at the 51st Annual Meeting of the American Association for the Study of Liver Diseases showing treatment is associated with a mean decrease in HBV DNA (10/31)

Gilead Sciences Inc. (GILD)

Tenofovir DF

Tenofovir disoproxil fumarate

HIV

Company presented data at the 5th International Conference on Drug Therapy in HIV Infection in Scotland; Phase II data indicate that the addition of tenofovir DF resulted in a significant reduction in HIV RNA in treatment-experienced patients (10/22)

ICN Pharmaceuticals (NYSE:ICN) and Schering-Plough Corp. (NYSE:SGP)

PEG-INTRON

Peginterferon alfa-2b

Chronic hepatitis C

Schering-Plough reported Phase III results at the 51st Annual Meeting of the American Association for the Study of Liver Diseases, showing combination therapy with PEG-INTRON and Rebetol achieved a 54% rate of sustained virologic response overall (10/31)

Intellivax International Inc.*

Nasal proteosome influenza vaccine

Nasally administered vaccine

Influenza

Company started a Phase I trial at the University of Rochester; study will compare the product with an injectable vaccine (10/13)

Maxim Pharmaceuticals (MAXM)

Maxamine

Histamine dihydrochloride

Chronic hepatitis C infection

Company announced 12-week results at the American Association for the Study of Liver Diseases showing triple-drug therapy with Maxamine, IFN-alpha and ribavirin achieved a complete biochemical response (10/31)

MedImmune Inc. (MEDI)

Snyagis

Palivizumab

Respiratory syncitial virus

Company announced data at the American Academy of Pediatrics that demonstrate the effectiveness of Synagis in reducing hospitalization rates and related costs due to infection (10/30)

Ribozyme Pharmaceuticals Inc. (RZYM)

Heptazyme

Antihepatitis C ribozyme

Hepatitis C

Company presented results at the American Association for the Study of Liver Diseases showing Heptazyme was well tolerated and demonstrated excellent bioavailability (10/31)

SciClone Pharmaceuticals (SCLN)

Zadaxin

Thymosin alpha 1; synthetic version of naturally occurring peptide hormone thymosin (immunomodulator)

Chronic hepatitis B

Company presented study results at the 51st Annual Meeting of the American Association for the Study of Liver Diseases confirming Zadaxin's ability to activate T cells (10/31)

Triangle Pharmaceuticals Inc. (VIRS)

Coviracil

Emtricitabine; a nucleoside analogue

Hepatitis B virus

Company reported Phase I/II results at the 51st Annual Meeting of the American Association for the Study of Liver Diseases showing Coviracil caused significant anti-HBV activity; a Phase III trial was initiated (10/30)

Trimeris Inc. (TRMS)

T-20

Fusion inhibitor

HIV

Company said T-20 is entering Phase III trials, one in North, Central and South America and one in Europe and Australia (10/3)

ViroPharma Inc. (VPHM)

VP14637

Small-molecule antiviral

Respiratory syncytial virus

Company initiated clinical trials to evaluate safety and pharmacokinetic profile in healthy volunteers (10/16)

XTL Biopharmaceuticals Ltd. (Israel; LSE:XTL)

HBV-AbsXTL (XTL-001)

Consists of two fully human monoclonal antibodies that recognize different areas of the virus and a range of viral sero types

Chronic hepatitis B virus

Company presented promising Phase I data at the 51st Annual Meeting of the American Association for the Study of Liver Diseases (10/30)

MISCELLANEOUS

Aastrom Biosciences Inc.

AastromReplicell System

Designed to operate a family of patient-specific cell therapy kits to produce cells

Osteoporosis

Company initiated a Phase I/II-trial at the University of Michigan (10/31)

Amgen Inc. (AMGN)

Anakinra

Recombinant form of natural interleukin-1Ra, designed to competitively bond to IL-1 receptors

Rheumatoid arthritis

Company announced late-stage results at the American College of Rheumatology annual meeting that showed anakinra may accelerate reduction in joint damage progression and improvement in the health-related quality of life of RA patients (10/29)

Amgen Inc. (AMGN)

Aranesp

Darbepoetin alfa; an erythropoietic protein

Chronic renal insufficiency

Data presented at the 33rd annual meeting of the American Society of Nephrology from Phase II/III trials suggest Aranesp manages anemia in patients with CRI (10/15)

BioMarin Pharmaceutical Inc. (BMRN)

rhASB

Recombinant human Arylsulfatase B, also known as recombinant human N-acetylgalactosamine-4-sulfatase

Mucopolysacch-aridosis (MPS) VI

Company initiated a Phase I/II trial designed to test safety and efficacy (10/12)

BioSpecifics Technologies Inc. (BSTC)

Cordase

Injectable collagenase treatment

Adhesive capsulitis (frozen shoulder)

University Hospital and Medical Center at Stony Brook, of New York, said a Phase I trial will begin shortly (10/20)

Bone Care International Inc. (BCII)

Hectorol (FDA-approved)

Capsules; doxercalciferol

End-stage renal disease

Reported Phase III results at the American Society of Nephrology meeting showed Hectorol reduced abnormally elevated parathyroid hormone by about 60% and did not produce significant side effects (10/16)

British Biotech plc (UK; LSE:BBG; BBIOY)

BB-2827

Collagenase inhibitor

Rheumatoid arthritis

Company announced that BB-2827 entered clinical development (10/17)

Cantab Pharmaceutical Inc. (UK; CNTBY; LSE:CTB) and Smith Kline Beecham plc (NYSE:SBH)

TH-GW

Vaccine

Genital warts

Company said results of the first two Phase II trials conducted by SKB showed no significant difference in genital wart recurrence in treated patients compared to the control group (10/18)

Celsion Corp. (AMEX:CLN)

Microwave Uroplasty

Low heat/outpatient treatment system by creating an opening in the urethra using a balloon catheter with a microwave antenna running up the center

Benign prostatic hyperplasia

Company began a pivotal Phase II multicenter trial (10/18)

Centocor Inc.* and Schering-Plough Corp. (NYSE:SGP)

Remicade (FDA-approved)

Infliximab

Rheumatoid arthritis

Two-year Phase III of Remicade in combination with methotrexate suggest that the benefits can be sustained beyond one year; results were presented at the American College of Rheumatology meeting (10/31)

Cognetix Inc.*

CGX-1007

Conopeptide isolated from the venom of predatory marine snails of the Conus species

Refractory epilepsy

Company initiated the first trial, a Phase I, double-blind, placebo-controlled trial involving intravenous delivery of CGX-1007 (10/11)

Columbia Laboratories Inc. (AMEX:COB)

Progressive Hydration Vaginal tablet

Testerone

Testosterone-deficiency in women

Company completed a Phase I trial of the tablet for women; study demonstrated the technology could deliver testosterone vaginally over a period of days (10/23)

Connetics Corp. (CNCT)

Relaxin

Naturally occurring hormone

Scleroderma

Company did not meet primary endpoint and said it will not file a BLA (10/9); Phase III data presented at the Relaxin 2000 Conference in Australia show statistically significant decreases in blood pressure and an increase in predicted creatinine clearance (10/26)

Entropin Inc. (ETOP)

Esterom solution

Topical medicinal preparation

Impaired range of motion

Company announced encouraging results from a preliminary Phase IIIa analysis of 362 patients with impaired shoulder function (10/2)

EpiGenesis Pharmaceuticals Inc.*

EPI-2010

Respirable antisense oligonucleotide

Asthma

Company began a randomized, double-blind, Phase I study to assess tolerability and pharmacokinetics of inhaled EPI-2010 (10/30)

GeneLabs Technologies Inc. (GNLB)

Aslera

GL701 or prasterone

Systemic lupus erythematosus

Company presented Phase III results at the 64th Annual Scientific Meeting of the American College of Rheumatology that showed Aslera improves bone mineral density and prevents BMD loss in female patients (10/31)

Genzyme General (GENZ)

Fabrazyme

Agalsidase beta; enzyme replacement therapy

Fabry disease

Presented positive Phase III trial results at the American Society of Human Genetics meeting (10/5)

Genzyme General (GENZ) and Pharming Group NV (AEX:PHAR; EASDAQ:PHAR)

Human alpha-Glucosidase

Enzyme replacement therapy; intravenous infusion of a recombinant form of human alpha-Glucosidase produced in CHO cells

Pompe disease

Presented Phase I/II results showing the product is capable of improving cardiac and skeletal muscle functions (10/5)

Immunex Corp. (IMNX)

Enbrel (FDA-approved)

Etanercept

Rheumatoid arthritis< /P>

Results presented at the 64th Annual Scientific Meeting of the American College of Rheumatology showed patients experienced sustained reduction of joint pain and swelling for as long as four years of treatment (10/29); two-year data comparing Enbrel with methotrexate supported the use of Enbrel as first-line treatment for moderately to severely active RA (10/30)

Isis Pharmaceuticals (ISIP)

ISIS 2302

Antisense inhibitor of intercellular adhesion molecule-1

Crohn's disease

Company is reinitiating development with a Phase III trial, despite failed Phase IIb trials (10/4)

Isis Pharmaceuticals (ISIP)

ISIS 104838

Inhibitor of TNF-alpha

Rheumatoid arthritis and Crohn's disease

Company initiated Phase I studies to investigate the safety and efficacy of the drug administered intravenously and subcutaneously (10/25)

Isotechnika Inc. (Canada; VSE:ISA)

ISA(TX)247

Immunosuppressive drug

Autoimmune diseases

Preliminary results of Phase Ic trials show the drug was well tolerated with no significant adverse events (10/30)

La Jolla Pharmaceutical Co. (LJPC)

LJP 394

Molecule (toleragen) that binds to the surface of B cells and shuts off production of antibodies to double-stranded DNA

Lupus

Company presented Phase II/III results at the 64th Annual Meeting of the American College of Rheumatology (10/18); company intends to enroll 300 patients in a Phase III trial (10/19)

Nastech Pharmaceutical Co. Inc. (NSTK)

Apomorphine

Intranasal apomorphine hydrochloride

Sexual dysfunction in women

Phase I trial results were positive with no serious side effects (10/4)

Nastech Pharmaceutical Co. Inc. (NSTK)

Apomorphine

Intranasal apomorphine hydrochloride

Erectile dysfunction

Company is beginning patient accrual for a Phase II trial; company presented data for male and female sexual dysfunction at the Female Sexual Function Forum in Boston (10/30)

NeoTherapeutics Inc. (NEOT)

Neotrofin

Leteprinim potassium; small-molecule compound debarrier that enhances nerve cell function by increasing levels of neurotrophic factor

Alzheimer's disease

Company presented Phase II/III results at the European C21 Conference showing that Neotrofin has been safe and well tolerated and has shown patient improvement in cognition and behavior (10/20)

Novavax Inc. (AMEX:NOX)

Estrasorb

Topical estrogen replacement therapy employs micellar nanoparticle technology designed to deliver 17B estradiol through the skin

Symptomatic post-menopause

Company completed enrollment of 200 women in a Phase III trial (10/5)

Pain Therapeutics Inc. (PTIE)

PTI-601

Opioid treatment

Moderate pain

Company initiated a Phase IIb trial (10/18)

Pain Therapeutics Inc. (PTIE)

PTI-555

Morphine

Pain

Company initiated two Phase IIb trials designed to demonstrate the drug's safety and efficacy (10/23)

Protein Design Labs Inc. (PDLI)

SMART Anti-Gamma Interferon

Antibody

Crohn's disease

Phase I results were presented at the 64th Annual Meeting of the American College of Rheumatology showing the antibody was safely administered and showed no serious adverse events; company plans to initiate a Phase I/II trial (10/30)

Scios Inc. (SCIO)

SCIO-469

Inhibitor of p38

Rheumatoid arthritis

Company announced the initiation of a Phase I, double-blind, placebo-controlled, dose-ranging study (10/31)

Symbollon Corp. (SYMBA)

IoGen

Molecular iodine

Fibrocystic breast disease

Company presented favorable results of a Phase II trial at the MASS Opportunities Conference (10/20)

Transkaryotic Therapies Inc. (TKTX)

Replagal

Enzyme replacement therapy

Fabry disease

Company presented pivotal Phase II clinical results at the American Society of Human Genetics meeting showing statistical significance in the reduction of pain and stabilization of kidney function (10/6)

Vivus Inc. (VVUS)

Alista

Formulation of alprostadil, a naturally occurring vasodilating agent

Female sexual dysfunction

Company began patient enrollment in the clinical program (10/26)

No Comments